Loren Cabral

Will we see more opportunity for Validation Professionals in 2025? The validation market is heating up as big players and industry shifts create new opportunities for CQV and Validation professionals. Here’s what’s driving the change: 📈 Biotech Expansion — With huge investments from Amgen ($1.5B), J&J ($2B), and Fujifilm Diosynth ($1.2B), demand for CQV engineers is set to rise. With many opportunities across Aseptic Processing, Equipment Validation and Automation. ⚙️ Tech-Enabled Validation — The shift to digital validation systems and paperless CQV is here. Companies are turning to cloud-based tools to streamline data capture and boost audit-readiness. 🌿 Sustainable Validation — As biopharma adopts green manufacturing, validation engineers must ensure compliance for eco-friendly production and energy-efficient systems. 💥 What’s Next? With 2025 a few weeks away I am looking to connect with CQV and Validation Consultants to discuss projects upcoming in Q1 next year. 👉 Do you think 2025 will have more opportunity that 2024? Let me know! #Validation #CQV #PharmaTrends #Biopharma #Innovation #AsepticProcessing #CellAndGeneTherapy #Sustainability

15

1 Comment

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

I have noticed many people with the green banner. I would welcome all of you to follow our page to ensure you know of all of the roles we are working on as they come in. With a quick click of that follow button, you will see our openings, HOT jobs that we spotlight and more. These posts are up to date and happen all week so don't miss out! Scientific Search

8

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

18

The Q3 Job Market Report from BioSpace just dropped, and you definitely want to check it out! The life sciences job market is going through some big changes, and keeping up with the latest info is super important for navigating it all. According to the new BioSpace data, there are some challenges but also plenty of opportunities coming up! 🔍 Key Insights from BioSpace's Q3 2024 Report: 1. Decrease in Job Postings:   - There were 21,548 jobs live on BioSpace in Q3 2024.   - This is a 12% decrease from 24,503 jobs in Q3 2023. 2. Increase in Job Competition:   - The job response rate (percentage of people applying after viewing) jumped from 9.8% to 14.8%, a 51% increase year-over-year.   - Notably, from July to September 2024, the response rate surged from 14.5% to 18.4%, a 26.9% increase. 3. Top States for Job Openings:   - California: 3,769 jobs   - Massachusetts: 3,110 jobs   - New Jersey: 2,513 jobs   - Illinois: 2,452 jobs   - New York: 1,717 jobs 4. Impact of Layoffs:   - In Q3 2024, there were 54 rounds of layoffs in biotech and pharma, affecting at least 3,700 employees.   Significant layoffs included:    - FibroGen, Inc.: Let go of 75% of its U.S.-based workforce (~356 people).    - GRAIL: Laid off about 350 employees.    - BioMarin Pharmaceutical Inc.: Cut 225 positions globally.    - Johnson & Johnson & Bayer: Combined layoffs of 288 employees in New Jersey. 💡 What This Means for You: - Increased Competition: With fewer job postings and more professionals in the market, it's crucial to differentiate yourself. - Strategic Job Hunting: According to Carina Clingman, PhD, CEO of Recruitomics Consulting, fall is prime time for job hunting in biotech. Companies aim to fill positions before the budget cycle ends around Thanksgiving. 📈 Emerging Opportunities:  - Johnson & Johnson is investing $2 billion in a new biologics manufacturing plant in Wilson, North Carolina, expected to create 420 new full-time, highly skilled jobs. Construction begins in the first half of 2024.  - Eli Lilly and Company is committing $4.5 billion to build a facility in Lebanon, Indiana, housing research and manufacturing. Set to open in late 2027, it will employ about 400 new engineers, scientists, lab technicians, and operations personnel.  - MassBio's 5-Year Plan: Aiming to create hundreds of new biopharma and life sciences positions in Massachusetts by 2030, focusing on supporting early-stage biotech growth. 🚀 Tips to Stay Ahead: - Update Your Skills: Leverage this time to enhance your expertise and stay competitive. - Network: Engage with industry peers and attend virtual or in-person events. - Stay Informed: Keep an eye on emerging biotech hubs and companies expanding their workforce. - Be Proactive: Tailor your applications and highlight how you can add value in this dynamic environment. Share your experiences or tips below. #Biotech #Pharma #JobMarket #CareerGrowth #LifeSciences

4

The Biopharma Job Market in 2024: A Reality Check I feel compelled to address some misconceptions about the current job market. While some recruiters may be expressing optimism about hiring picking up or the market turning around, the data tells a different story. Let's look at the facts: Layoff Trends: Q2 2024 saw a significant increase in biopharma layoffs, with at least 7,616 workers impacted. This is more than triple the 2,398 layoffs reported in Q1 2024. Major Players Affected: Industry giants like Novartis, Indivior, CureVac, and Takeda have all announced substantial job cuts in recent months. Ongoing Restructuring: Many companies are still in the midst of restructuring efforts, with some planning layoffs that will continue into late 2024 and beyond. Biotech Volatility: While there are pockets of growth, particularly in well-funded startups, the overall biotech sector remains volatile. What This Means for Job Seekers: Be Cautious: Exercise caution when hearing overly optimistic projections from recruiters. Always verify claims with industry data. Stay Informed: Keep abreast of industry trends, company financials, and pipeline news to make informed decisions. Diversify Your Search: Consider roles in emerging biotech startups or adjacent industries that value pharma experience. Enhance Your Skills: Focus on developing skills that are in high demand, such as data analytics, digital health, or regulatory affairs. Network Strategically: Build relationships within the industry, not just for immediate opportunities but for long-term career growth. As recruiters, our role is to provide accurate, data-driven insights to both clients and candidates. While we all hope for market improvement, it's crucial to approach the current landscape with realism and strategic thinking. What strategies are you employing in this challenging market? Let's discuss in the comments. #PharmaceuticalIndustry #BiotechJobs #CareerAdvice #RecruitmentTrends

57

10 Comments

🔍 As the biotech industry evolves, professionals must adapt to changing job trends. Here are strategies to thrive in this shifting landscape: - Embrace Continuous Learning: Stay updated on the latest advancements to remain competitive. - Network Strategically: Build connections within the industry to explore new opportunities. - Leverage Transferable Skills: Highlight versatile skills applicable across various roles. - Seek Mentorship: Learn from experienced professionals to navigate career challenges effectively. - Embrace Flexibility: Be open to diverse roles and career paths within the biotech sector. - Stay Resilient: Develop a growth mindset to overcome setbacks and seize new opportunities. Let's discuss: How do you navigate career changes in the biotech industry? #BiotechCareer #ProfessionalDevelopment #IndustryInsights

2

The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for cancer to rare diseases. 🧬 Stay ahead of the latest in biotech and learn how these FDA decisions could shape the future of healthcare.

1

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐬𝐢𝐭𝐞𝐬 𝐬𝐞𝐞𝐧 𝐚𝐬 𝐡𝐨𝐭 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐲 𝐟𝐨𝐫 𝐏𝐄 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Private equity is increasingly investing in clinical trial sites due to industry demand for larger networks, as shown by PitchBook's analysis of first quarter 2024 deal activity. Contract research organizations (CROs) are acquiring trial sites to enhance their service offerings, exemplified by American Clinical Research Services acquiring Elixia and Alcanza Clinical Research's focus on sites in Hispanic areas. This trend is part of a broader movement towards vertical and horizontal consolidation, aiming to create end-to-end drug development capabilities. #privateequity #clinicalresearchsites

4

Key PDUFA dates in Q1 2025. But for those of us in recruitment, PDUFA dates signal an exciting opportunity for growth, innovation, and hiring. It may seem simple, but when a drug is approved, it often leads to expansion, requiring new teams to scale up clinical trials, production, and marketing efforts. This creates a surge in hiring for top talent in areas like regulatory affairs, clinical operations, quality assurance, marketing, commercialisation etc. For job seekers: If you’re looking to be part of something impactful, keep an eye on the PDUFA dates. They represent the opportunity to work with groundbreaking therapies and contribute to the future of healthcare. Here are 5 to watch out for in the next 3 months: Axsome Therapeutics, Inc. - AXS-07 Neurotech Pharmaceuticals, Inc. - NT-501 Alnylam Pharmaceuticals - Vutrisiran GSK - Gepotidacin Milestone Pharmaceuticals, Inc. - Etripamil Nasal Spray Apsida Life Science

13

AI in Regulatory Affairs: Your Competitive Edge for 2025 🌟 If you’re a Regulatory Affairs Manager or Senior Regulatory Affairs Manager exploring your next career opportunity, the rise of artificial intelligence (AI) in regulatory affairs is an area you could differentiate yourself from other candidates with. As the pharmaceutical industry embraces AI to streamline processes and stay ahead of global regulatory demands, hiring managers are seeking professionals who not only understand the complexities of compliance but also see AI as a strategic tool. Here’s why AI-savvy regulatory experts will be in high demand: 💼 AI Skills Signal Leadership Potential Employers are looking for regulatory professionals who can use AI tools to accelerate submissions, manage compliance proactively, and streamline global regulatory workflows. Highlighting experience with AI-driven tools or a willingness to learn can set you apart. 🚀 Strategic Problem Solvers AI is transforming regulatory roles from operational to strategic. Showcasing how you’ve driven innovation, embraced new technologies, or improved processes in past roles demonstrates your readiness for the future. 📊 Adaptability Is the New Must-Have With AI automating repetitive tasks, today’s regulatory leaders are focusing on big-picture strategy. Companies want people who can interpret insights from AI systems and use these insights to proactively plan for the future 🔎 Upskilling for the AI Revolution Learning new skills is key for all of us, and demonstrating new tools and incorporating data and systems such as automation platforms, predictive analytics andpharmacovigilance software on your cv are great ways to show you are preparing for the future. Your Job Hunt for 2025: 👉 Highlight your adaptability and strategic mindset. 👉 Speak to your experience with, or openness to, AI technologies. 👉 Show how you’ve embraced innovation to solve challenges in your past roles. The regulatory landscape is evolving fast, and those who position themselves as AI-savvy, strategic and future-focused professionals will stand out. How are you preparing for the future of regulatory affairs? If you’re job hunting, I’d love to hear how you’re showcasing your readiness for the AI-driven regulatory world. Please reach out via this post or DM. #RegulatoryAffairs #AI #JobHunting #PharmaCareers #PharmaceuticalIndustry #teampsp

5

1 Comment

The FDAs rule on Laboratory Developed Tests is officially here. What does this mean for your team? An ALKU expert can help answer that question, or assist in execution if a roadmap has already been identified. Reach out today to speak to some of the best in the industry, who exclusively consult through ALKU. #FDA #LDT #LaboratoryDevelopedTests #FDACompliance #MedicalDevice

21

🚨 Pfizer & Flagship Pioneering Expand Their Billion-Dollar Collaboration! 🚨 Pfizer and Flagship are doubling down on obesity and lung cancer with innovative partnerships: 💡 Ampersand Biomedicines: Leveraging their AND platform to target metabolic pathways for obesity treatment. 💡 Montai Therapeutics: Using computational tools to decode biological pathways and develop precision small molecules for lung cancer. This marks the 3rd & 4th partnerships under their 10-program pact, showcasing a new Innovation Supply Chain in biopharma. #Biotech #Collaboration #Innovation #Pfizer #FlagshipPioneering #Healthcare

3

1 Comment

📊 Navigating the Biopharma Job Market in 2024: Key Insights, Trends, and Strategies 📈 Both job seekers and employers are navigating significant changes. Here’s a deep dive into the current trends shaping our industry, along with practical strategies to help you succeed in today’s competitive job market: 🔍 Hiring & Salary Trends High Demand for Specialized Expertise: With advances in immunotherapy, CRISPR gene editing, and personalized medicine, there’s a rising demand for specialized professionals. Roles in bioinformatics, clinical research, and data analytics are particularly sought after. Remote Work is Here to Stay: Many companies have embraced hybrid work models post-pandemic. Professionals now have the flexibility to contribute effectively from anywhere. Rising Salary Benchmarks: To attract top talent, salaries are climbing. Recent studies indicate a 10-15% increase in compensation for mid-to-senior roles in biopharma. 🛑 Challenges for Job Seekers & Employers Talent Shortages: Despite numerous job openings, there’s a notable shortage of candidates for highly specialized roles. Upskilling and continuous development are crucial to filling this gap. Keeping Pace with Rapid Innovation: Both employers and employees need to stay up-to-date with fast-moving technological advancements—a challenge, but also an exciting growth opportunity! Changing Hiring Processes: Companies are increasingly leveraging AI tools like applicant tracking systems (ATS) and automated video interviews to streamline hiring. While these tools improve efficiency, they can also make the process feel impersonal. 🌟 Personal Insights & Strategies From my experience helping candidates 🚀, here are a few strategies to help you thrive: Embrace Lifelong Learning: Stay relevant by enrolling in online courses, attending conferences, and actively networking within professional communities. Sharpen Your Digital Skills: Familiarize yourself with AI and machine learning applications in biopharma. Platforms like LinkedIn Learning and Coursera are great resources to stay ahead of digital trends. Leverage Technology for Job Search: Use AI tools like ChatGPT to refine your resume or practice for interviews. Tools like Clay can help you organize and streamline your job search across multiple platforms. Don’t Forget the Human Touch: In an age of automation, human connection is more important than ever. Personalize your job applications and engage directly with connections on LinkedIn or through email introductions. 💬 Let’s Connect! What trends have you noticed in the biopharma job market? How are you tackling these challenges? Drop a comment below—I’d love to hear your insights and experiences! By staying proactive and embracing the latest trends 📚🔧🔬, we can not only remain relevant but continue to thrive in this exciting industry. 🌍💡🏆 #Biopharma #JobMarket2024 #CareerGrowth #ContinuousLearning #AIinBiopharma

7

4 Comments

Adapting to Thrive: Overcoming Challenges in Med-Tech Leadership Leaders in med-tech, you face unique challenges. -The rapid pace of technology. -Navigating complex regulations. -Finding and retaining top talent. But these challenges also present opportunities. -Embrace continuous learning. -Innovate and adapt quickly. -Build a dynamic and skilled team. Your efforts will drive the next wave of medical technology innovations. Stay focused, stay determined, and lead with vision. What's your strategy for keeping up with tech advancements?

3

📣 For those going to the ASA Biopharmaceutical Section Statistics Workshop this week, Stop by Booth #18 to meet my teammates: Lei Wang, Helena Fan, & Bill Emker. American Statistical Association - ASA #pharma #fda #statistics #statisticians #biostatisticians #biostatistics #datascience

1

The passage of the BIOSECURE Act in the U.S. House, now heading to the Senate, could have a major impact on the pharma/biotech industry. This legislation restricts U.S. biotech companies from collaborating with certain Chinese firms, such as WuXi AppTec, which may reshape hiring trends across both countries. As a recruiter in this space, I see opportunities for U.S.-based talent increasing as companies look to bring operations home. However, Chinese candidates and firms may face more hurdles, requiring strategic adaptations. Clients on both sides will need to adjust their hiring strategies, possibly turning to more localized markets. Navigating this shifting landscape will be crucial for supporting both candidates and clients as the biotech industry evolves under these new regulations. Exciting times ahead, but also a reminder of how fast things can change! #pharma #biotech #recruitment #BIOSECURE #hiringtrends #USChina #innovation https://lnkd.in/g4_zdCzB

9

🚀 Bristol Myers Squibb Q2 2024: Strong Results and Upgraded Guidance! 💊 Bristol Myers Squibb (BMS) has reported impressive second-quarter results, driven by robust sales from Eliquis and Opdivo. The company is also making significant strides in cost-cutting, aiming for $1.5 billion in savings by 2025. 📊 Key Highlights: -Q2 Revenues: $12.2 billion, an 11% YoY increase. -Eliquis: $3.5 billion in global sales, up 7%. -Opdivo: $2.4 billion in sales, up 11%. -Revlimid: $1.3 billion, despite an 8% decline. -CAR-T Therapies: Breyanzi ($153 million, 53% growth) and Abecma ($95 million). 💡 Encouraged by these results, BMS has raised its full-year 2024 guidance, now expecting earnings per share of 60 to 90 cents. 💼 As part of its strategic realignment, BMS plans to lay off 2,200 employees by the end of 2024, prioritizing investments with the greatest potential. 🔬 R&D Update: -Cendakimab: Successful Phase III trial in eosinophilic esophagitis. -Alnuctamab: Development discontinued for multiple myeloma. BMS continues to innovate and adapt, ensuring a promising future for its portfolio and stakeholders. #BMS #Pharma #Q2Results #Healthcare #Innovation #CostCutting #Eliquis #Opdivo #Revlimid #CARTTherapy #Biotech #MedicalResearch #BusinessGrowth

3

1 Comment

Top 10 most anticipated drug launches of 2024! 🌟 Curious about who's made the list? 👀 Check out this list highlighting the biggest potential new drugs of the year for 2024 😎 Are there any notable ones missing❓ #LifeSciences #DrugLaunches2024 #Pharmacutical #BioTech

16